β-Amyloid 31-35

β-Amyloid 31-35 is a synthetic peptide fragment derived from the C-terminal region of the amyloid beta (Aβ) protein, a sequence that has garnered significant attention in neurodegenerative research. As a short, hydrophobic segment of the full-length Aβ peptide, it serves as a focused model for investigating the molecular determinants of amyloid aggregation, toxicity, and protein-protein interactions. Its unique sequence and biophysical properties make it a valuable tool for dissecting the minimal structural requirements underlying amyloidogenic behavior and for elucidating mechanisms relevant to protein misfolding disorders.

Aggregation studies: Researchers frequently employ β-Amyloid 31-35 in aggregation assays to probe the self-assembly and fibrillization processes characteristic of amyloidogenic peptides. Due to its propensity to form ordered aggregates in vitro, this peptide fragment provides a simplified, yet representative, system for examining the kinetics and morphology of amyloid fibril formation. Such studies are instrumental in identifying the sequence determinants that drive aggregation, as well as in evaluating the effects of environmental factors or small molecule modulators on amyloid assembly pathways.

Neurotoxicity modeling: The β-Amyloid 31-35 peptide is widely used in cellular and biochemical models to investigate mechanisms of peptide-induced cytotoxicity. Its ability to induce membrane disruption, oxidative stress, and apoptotic signaling in neuronal and non-neuronal cells offers a tractable platform for studying the molecular underpinnings of amyloid toxicity. These models are essential for delineating the pathways by which amyloid fragments contribute to cellular dysfunction, providing insight into the broader context of neurodegenerative disease research.

Membrane interaction studies: Owing to its amphipathic nature and hydrophobic amino acid composition, β-Amyloid 31-35 serves as a model system for exploring peptide-membrane interactions. Investigations utilizing this fragment help clarify how short amyloidogenic peptides interact with lipid bilayers, induce membrane permeabilization, and alter biophysical membrane properties. Such studies are fundamental for understanding the role of membrane disruption in amyloid-related cytotoxicity and for developing strategies to mitigate these effects.

Structure-activity relationship analysis: The minimal length and defined sequence of β-Amyloid 31-35 make it an ideal candidate for systematic structure-activity relationship (SAR) studies. By introducing targeted modifications or substitutions within the peptide, researchers can dissect the contribution of individual residues to aggregation propensity, toxicity, and biophysical behavior. SAR analyses using this fragment facilitate the rational design of peptide-based inhibitors or probes and enhance understanding of the sequence features essential for amyloid formation.

Analytical method development: β-Amyloid 31-35 is also utilized as a reference standard or calibrant in the development and optimization of analytical techniques, including high-performance liquid chromatography (HPLC), mass spectrometry, and spectroscopy-based assays. Its well-characterized properties allow for the establishment of robust protocols for peptide detection, quantification, and structural analysis, thereby supporting quality control and reproducibility in peptide research workflows.

1. Myotropic activity of allatostatins in tenebrionid beetles

2. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance

3. Implications of ligand-receptor binding kinetics on GLP-1R signalling

4. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

5. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury